New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:15 EDTARRY, CGIX, EXEL, GILD, MNK, QSII, AHS, SGENUBS to hold a conference
2014 Global Healthcare Conference to be held in New York on May 19-21 with webcasted company presentations to begin on May 20 at 8 am; not all company presentations may be webcasted. Webcast Link
News For ARRY;CGIX;EXEL;GILD;MNK;QSII;AHS;SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 13, 2014
07:56 EDTGILDGilead Harvoni pricing 'very reasonable,' says RBC Capital
Subscribe for More Information
07:52 EDTCGIXCancer Genetics partners with Columbia University oncology researchers
Cancer Genetics has entered into a research collaboration with Columbia University's Azra Raza, MD, director of the MDS Center and assistant professor of medicine at Columbia University Medical Center, and Siddhartha Mukherjee, MD, PhD, assistant professor of medicine at CUMC, to identify more accurate diagnostic and prognostic markers for myelodysplastic syndromes, as well as novel therapies to target this class of bone marrow cancers. The ultimate goal of the collaboration is to develop personalized therapy for MDS patients and to enable accurate prediction of future treatment needs before patients become resistant to their current therapy or before their MDS progresses to the more aggressive acute myeloid leukemia.
07:39 EDTGILDPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
October 10, 2014
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
08:53 EDTARRYArray drug has little evidence of being effective, says Summer Street
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
07:16 EDTMNKAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
October 9, 2014
11:43 EDTGILDStocks with call strike movement; GILD EWZ
Gilead (GILD) February 120 call option implied volatility increased 3% to 38, MSCI Brazil Index (EWZ) February 58 call option implied volatility increased 3% to 38 according to IVolatility.
09:20 EDTARRYSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:28 EDTGILDGilead to be challenged by AbbVie in HCV near-term, says Bernstein
Subscribe for More Information
06:39 EDTMNKMallinckrodt price target raised to $110 from $95 at Jefferies
Jefferies raised its price target for Mallinckrodt shares to $110 ahead of the company's October 14 analyst day and keeps a Buy rating on the name. The firm says recent trends show continued strength for Ofirmev.
October 8, 2014
16:26 EDTGILDOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTGILDOptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
15:49 EDTGILDAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
07:19 EDTMNKCBI to hold a conference
Subscribe for More Information
07:18 EDTGILDInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use